25519-79-3

Basic information

• Product Name: 1-ACETYL-4-BENZOYLPIPERIDINE
• Synonyms: 1-ACETYL-4-BENZOYLPIPERIDINE;ETHANONE, 1-(4-BENZOYL-1-PIPERIDINYL)-;1-(4-Benzoyl-1-piperidinyl)ethanone
• CAS NO: 25519-79-3
• Molecular Formula: C₁₄H₁₇NO₂
• Molecular Weight: 231.29
• Product Categories: Neurochemicals;Aromatics;Heterocycles
• Mol File: 25519-79-3.mol
• Article Data: 11

Chemical Properties

• Melting Point: 83-85°C
• Appearance: /
• Storage Temp.: -20°C Freezer
• Solubility: Acetone, Ethyl Acetate, Methanol
• CAS DataBase Reference: 1-ACETYL-4-BENZOYLPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-ACETYL-4-BENZOYLPIPERIDINE(25519-79-3)
• EPA Substance Registry System: 1-ACETYL-4-BENZOYLPIPERIDINE(25519-79-3)

Safety Data

• Hazardous Substances Data: 25519-79-3(Hazardous Substances Data)

Usage

Description

1-ACETYL-4-BENZOYLPIPERIDINE is a synthetic intermediate that is used in the preparation of CNS depressants. It is an off-white solid with specific chemical properties that make it suitable for this application.

Uses

Used in Pharmaceutical Industry:
1-ACETYL-4-BENZOYLPIPERIDINE is used as a synthetic intermediate for the production of CNS depressants. Its chemical properties allow it to be a key component in the synthesis of these medications, which are used to treat various conditions such as anxiety, insomnia, and seizures.

Upstream product

• 59084-16-1 1-acetylpiperidine-4-carbonyl chloride 
• 71-43-2 benzene 
• 108-24-7 acetic anhydride 
• 25519-80-6 4-(benzoyl)piperidine hydrochloride 
• 498-94-2 isonipecotic acid 
• 25503-90-6 1-acetyl-piperidine-4-carboxylic acid 

Downstream Products

• 58113-24-9 1-acetyl-α-cyclohexyl-α-phenyl-4-piperidinemethanol 
• 58113-26-1 α-phenyl-α-<3-(trifluoromethyl)phenyl>-4-piperidinemethanol 
• 37586-22-4 4-benzoylpiperidine 
• 1599531-56-2 C₃₄H₃₃ClN₄O₃ 
• 1599531-55-1 C₃₄H₃₃ClN₄O₃ 
• 25519-80-6 4-(benzoyl)piperidine hydrochloride 

Relevant articles and documents

Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor

Monoacylglycerol lipase (MAGL) is the enzyme degrading the endocannabinoid 2-arachidonoylglycerol, and it is involved in several physiological and pathological processes. The therapeutic potential of MAGL is linked to several diseases, including cancer. The development of MAGL inhibitors has been greatly limited by the side effects associated with the prolonged MAGL inactivation. Importantly, it could be preferable to use reversible MAGL inhibitors in vivo, but nowadays only few reversible compounds have been developed. In the present study, structural optimization of a previously developed class of MAGL inhibitors led to the identification of compound 23, which proved to be a very potent reversible MAGL inhibitor (IC50 = 80 nM), selective for MAGL over the other main components of the endocannabinoid system, endowed of a promising antiproliferative activity in a series of cancer cell lines and able to block MAGL both in cell-based as well as in vivo assays.

PIPERIDINE UREA DERIVATIVES

Compounds of the formula I in which R1-R3 have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

PHENYL LINKED QUINOLINYL MODULATORS OF RORyt

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also